Answers are grounded in this paper and cite their sources.
Randomized trial evaluates overall survival in patients with specific gastric cancer types, suggesting new treatment options.
There remains an unmet need for additional treatment options for patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced (LA) unresectable, or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma whose tumors are claudin 18 isoform 2 (CLDN18.2)-positive and programmed death-ligand 1 (PD-L1)-positive. The phase 2 ILUSTRO trial previously demonstrated promising clinical activity with the combination of zolbetuximab plus chemotherapy and checkpoint inhibitor therapy in patients with HER2-negative, LA unresectable, or mG/GEJ adenocarcinoma whose tumors were CLDN18.2-positive, warranting further exploration. In LUCERNA, a multicenter, double-blind, phase III trial, patients with HER2-negative, LA unresectable, or mG/GEJ adenocarcinoma whose tumors are CLDN18.2-positive and PD-L1-positive will be randomly assigned 1:1 to either first-line zolbetuximab plus pembrolizumab and chemotherapy (a capecitabine and oxaliplatin regimen, CAPOX; or a modified folinic acid, fluorouracil, and oxaliplatin regimen, mFOLFOX6) or placebo plus pembrolizumab and chemotherapy. The primary endpoint is overall survival. Key secondary endpoints are progression-free survival and objective response rate. Additional secondary endpoints include duration of response and safety. The results of this trial have the potential to support a new standard-of-care option in this patient population.
No takes yet. Share an insight, caveat, or question.
Shitara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: